- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608; HuLuc63)
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 748 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 70 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 744
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumors
- Interventions
- Dexamethasone, Placebo
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2028
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Cobalamin, Dexamethasone, Docetaxel, Folic Acid, Gemcitabine, Nogapendekin Alfa, Pembrolizumab, Pemetrexed, Ramucirumab
- Dietary Supplement · Drug · Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 350
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Little Rock, Arkansas + 280 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 569 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Gainesville, Florida • West Palm Beach, Florida + 20 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill, Bortezomib Injection
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
- Interventions
- Palbociclib Oral Capsule, Intrathecal Triple Therapy, Dexamethasone, Bortezomib, Dasatinib, Doxorubicin, Ruxolitinib
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Iberdomide, Belantamab Mafodotin, Dexamethasone, Echocardiography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
- Drug · Biological · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 43
- States / cities
- Ames, Iowa • Boone, Iowa • Fort Dodge, Iowa + 30 more
- Conditions
- Myeloma
- Interventions
- Lenalidomide, Dexamethasone, All-Trans Retinoic Acid (ATRA)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Selinexor, Liposomal doxorubicin, Dexamethasone
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Detroit, Michigan
- Conditions
- Elbow Fracture
- Interventions
- Glucocorticoids, Saline
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Adrenocortical Adenoma, Endometrial Stromal Sarcomas
- Interventions
- MRI, CT or ultrasound was permitted if MRI was contraindicated, Dexamethasone Supression Test, Sonogram, Biopsy, BGG492
- Procedure · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 4
- States / cities
- Tallahassee, Florida • Baltimore, Maryland • Hoffman, New Jersey + 1 more
- Conditions
- Nausea, Vomiting
- Interventions
- Ondansetron, Dexamethasone, Aprepitant
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Relapsed/Refractory, Multiple Myeloma
- Interventions
- Mezagitamab, Pomalidomide, Dexamethasone
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 7
- States / cities
- Duarte, California • St Louis, Missouri • New York, New York + 3 more
- Conditions
- Lymphoma, Multiple Myeloma
- Interventions
- Lenalidomide, Dexamethasone, Dexamethasone (Oral), Dexamethasone (IV), Elotuzumab (BMS-901608; HuLuc63)
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 646 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 63
- States / cities
- Muscle Shoals, Alabama • Tucson, Arizona • Berkeley, California + 53 more
- Conditions
- Waldenstrom's Macroglobulinemia
- Interventions
- pomalidomide, dexamethasone, rituximab
- Drug
- Lead sponsor
- Steven P. Treon, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sudden Sensorineural Hearing Loss
- Interventions
- Statin, methylprednisolone, dexamethasone, Placebo
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Graft vs Host Disease
- Interventions
- Topical Dexamethasone, Placebo
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 12 Years to 110 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Refractory Multiple Myeloma
- Interventions
- azacitidine, lenalidomide, dexamethasone, DNA methylation analysis, gene expression analysis, bone marrow aspiration, immunohistochemistry staining method, reverse transcriptase-polymerase chain reaction, flow cytometry
- Drug · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Anterior Cruciate Ligament Injury, ACL Injury, ACL - Anterior Cruciate Ligament Rupture
- Interventions
- Femoral Nerve Block, Adductor Nerve Block, No Block
- Procedure · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Shoulder Arthropathy, Shoulder Pain
- Interventions
- Celecoxib, Pregabalin, Tramadol, Dexamethasone, Acetaminophen, Ropivicaine, Epinephrine, Ketorolac, Tizanidine, Magnesium, Ibuprofen, Oxycodone Hydrochloride 5 Mg
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma
- Interventions
- SOM230, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Venetoclax, Bortezomib, Dexamethasone, Placebo for venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Durham, North Carolina • Canton, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- Thalidomide, Dexamethasone, DOXIL
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 58
- States / cities
- Fountain Valley, California • Greenbrae, California • La Verne, California + 55 more
- Conditions
- Multiple Myeloma
- Interventions
- Pomalidomide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Hackensack, New Jersey + 1 more